nach oben

Erschienen in:

01.02.2015 | Original Research Article

Consensus Recommendations for Systematic Evaluation of Drug–Drug Interaction Evidence for Clinical Decision Support

verfasst von: Richard T. Scheife, Lisa E. Hines, Richard D. Boyce, Sophie P. Chung, Jeremiah D. Momper, Christine D. Sommer, Darrell R. Abernethy, John R. Horn, Stephen J. Sklar, Samantha K. Wong, Gretchen Jones, Mary L. Brown, Amy J. Grizzle, Susan Comes, Tricia Lee Wilkins, Clarissa Borst, Michael A. Wittie, Daniel C. Malone

Erschienen in: Drug Safety | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Healthcare organizations, compendia, and drug knowledgebase vendors use varying methods to evaluate and synthesize evidence on drug–drug interactions (DDIs). This situation has a negative effect on electronic prescribing and medication information systems that warn clinicians of potentially harmful medication combinations.

Objective

The aim of this study was to provide recommendations for systematic evaluation of evidence for DDIs from the scientific literature, drug product labeling, and regulatory documents.

Methods

A conference series was conducted to develop a structured process to improve the quality of DDI alerting systems. Three expert workgroups were assembled to address the goals of the conference. The Evidence Workgroup consisted of 18 individuals with expertise in pharmacology, drug information, biomedical informatics, and clinical decision support. Workgroup members met via webinar 12 times from January 2013 to February 2014. Two in-person meetings were conducted in May and September 2013 to reach consensus on recommendations.

Results

We developed expert consensus answers to the following three key questions. (i) What is the best approach to evaluate DDI evidence? (ii) What evidence is required for a DDI to be applicable to an entire class of drugs? (iii) How should a structured evaluation process be vetted and validated?

Conclusion

Evidence-based decision support for DDIs requires consistent application of transparent and systematic methods to evaluate the evidence. Drug compendia and clinical decision support systems in which these recommendations are implemented should be able to provide higher-quality information about DDIs.

Nur mit Berechtigung zugänglich

Aspden P, Institute of Medicine (U.S.). Committee on identifying and preventing medication errors. Preventing medication errors. Washington, DC: National Academies Press; 2007.

Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug–drug interactions. Expert Opin Drug Saf. 2012;11(1):83–94.CrossRefPubMed

Centers for Disease Control and Prevention FASTSTATS—Emergency Department Visits. 2012. US Department of Health and Human Services. [cited 12/06/2013]; Available from: http://www.cdc.gov/nchs/fastats/ervisits.htm.

Centers for Disease Control and Prevention FASTSTATS—Hospital Utilization. 2010. US Department of Health and Human Services. [cited 12/06/2013]; Available from: http://www.cdc.gov/nchs/fastats/hospital.htm.

Centers for Medicare and Medicaid Services. Eligible Professional Meaningful Use Core Measures: Measure 2 of 15. 2010. US Department of Health and Human Services. [cited 01/09/2013]; Available from: http://www.cms.gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/downloads/2_Drug_Interaction_ChecksEP.pdf.

Hatton RC, Rosenberg AF, Morris CT, McKelvey RP, Lewis JR. Evaluation of contraindicated drug–drug interaction alerts in a hospital setting. Ann Pharmacother. 2011;45(3):297–308.CrossRefPubMed

Shah VS, Weber RJ, Nahata MC. Contradictions in contraindications for drug–drug interactions. Ann Pharmacother. 2011;45(3):409–11.CrossRefPubMed

Horn JR, Hansten PD. Comment: evaluation of contraindicated drug–drug interaction alerts in a hospital setting. Ann Pharmacother. 2011;45(6):826 (author reply-7).CrossRefPubMed

Kesselheim AS, Cresswell K, Phansalkar S, Bates DW, Sheikh A. Clinical decision support systems could be modified to reduce ‘alert fatigue’ while still minimizing the risk of litigation. Health Aff (Millwood). 2011;30(12):2310–7.CrossRefPubMed

10.

Saverno KR, Hines LE, Warholak TL, Grizzle AJ, Babits L, Clark C, et al. Ability of pharmacy clinical decision-support software to alert users about clinically important drug–drug interactions. J Am Med Inform Assoc. 2011;18(1):32–7.CrossRefPubMedCentralPubMed

11.

Metzger J, Welebob E, Bates DW, Lipsitz S, Classen DC. Mixed results in the safety performance of computerized physician order entry. Health Aff (Millwood). 2010;29(4):655–63.CrossRefPubMed

12.

Abarca J, Colon LR, Wang VS, Malone DC, Murphy JE, Armstrong EP. Evaluation of the performance of drug–drug interaction screening software in community and hospital pharmacies. J Manag Care Pharm. 2006;12(5):383–9.PubMed

13.

van der Sijs H, Aarts J, Vulto A, Berg M. Overriding of drug safety alerts in computerized physician order entry. J Am Med Inform Assoc. 2006;13(2):138–47.CrossRefPubMedCentralPubMed

14.

Miller AM, Boro MS, Korman NE, Davoren JB. Provider and pharmacist responses to warfarin drug–drug interaction alerts: a study of healthcare downstream of CPOE alerts. J Am Med Inform Assoc. 2011;18(Suppl 1):i45–50.CrossRefPubMedCentralPubMed

15.

Weingart SN, Toth M, Sands DZ, Aronson MD, Davis RB, Phillips RS. Physicians’ decisions to override computerized drug alerts in primary care. Arch Intern Med. 2003;163(21):2625–31.CrossRefPubMed

16.

Grizzle AJ, Mahmood MH, Ko Y, Murphy JE, Armstrong EP, Skrepnek GH, et al. Reasons provided by prescribers when overriding drug–drug interaction alerts. Am J Manag Care. 2007. p. 573–8 (United States).

17.

Caccia S, Garattini S, Pasina L, Nobili A. Predicting the clinical relevance of drug interactions from pre-approval studies. Drug Saf. 2009;32(11):1017–39.CrossRefPubMed

18.

Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165(10):1095–106CrossRefPubMed

19.

Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol. 2008;48(6):662–70.CrossRefPubMed

20.

Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007;41(4):674–80.CrossRefPubMed

21.

Hines LE, Malone DC, Murphy JE. Recommendations for generating, evaluating, and implementing drug–drug interaction evidence. Pharmacotherapy. 2012;32(4):304–13.CrossRefPubMed

22.

Hansten PD, Horn JR, Hazlet TK. ORCA: OpeRational ClassificAtion of drug interactions. J Am Pharm Assoc. 2001;41(2):161–5.

23.

Ridgeley MS, Greenberg MD. Too many alerts, too much liability: sorting through the malpractice implications of drug–drug interaction clinical decision support. Saint Louis Univ J Health Law Policy. 2012;5(257):257–96.

24.

Oates JA. Chapter 5. The science of drug therapy. In: Brunton LL, editor. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 11th ed. McGraw-Hill, Medical Publishing Division; 2006.

25.

Hines LE, Murphy JE. Potentially harmful drug–drug interactions in the elderly: a review. Am J Geriatr Pharmacother. 2011;9(6):364–77.CrossRefPubMed

26.

Talbot JCC, Aronson JK, Stephens MDB. Stephens’ detection and evaluation of adverse drug reactions : principles and practice. 6th ed. Chichester: Wiley; 2011.CrossRef

27.

Food and Drug Administration. Title 21–Food and Drugs Chapter I–Food and Drug Administration; US Department of Health and Human Services Subchapter D–Drugs for Human Use. 2013. [cited 7/28/14]; Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=320.33.

28.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.CrossRefPubMed

29.

Hutchinson TA, Lane DA. Assessing methods for causality assessment of suspected adverse drug reactions. J Clin Epidemiol. 1989;42(1):5–16.CrossRefPubMed

30.

Böttiger Y, Laine K, Andersson ML, Korhonen T, Molin B, Ovesjö ML, et al. SFINX-a drug–drug interaction database designed for clinical decision support systems. Eur J Clin Pharmacol. 2009;65(6):627–33.CrossRefPubMed

31.

van Roon EN, Flikweert S, le Comte M, Langendijk PN, Kwee-Zuiderwijk WJ, Smits P, et al. Clinical relevance of drug–drug interactions : a structured assessment procedure. Drug Saf. 2005;28(12):1131–9.CrossRefPubMed

32.

Boyce R, Collins C, Horn J, Kalet I. Computing with evidence Part II: an evidential approach to predicting metabolic drug–drug interactions. J Biomed Inform. 2009;42(6):990–1003.CrossRefPubMedCentralPubMed

33.

Boyce RD, Handler SM, Karp JF, Hanlon JT. Age-related changes in antidepressant pharmacokinetics and potential drug–drug interactions: a comparison of evidence-based literature and package insert information. Am J Geriatr Pharmacother. 2012;10(2):139–50.CrossRefPubMedCentralPubMed

34.

Boyce RD, Collins C, Clayton M, Kloke J, Horn JR. Inhibitory metabolic drug interactions with newer psychotropic drugs: inclusion in package inserts and influences of concurrence in drug interaction screening software. Ann Pharmacother. 2012;46(10):1287–98.CrossRefPubMed

35.

McDonagh MS, Peterson K, Balshem H, Helfand M. US Food and Drug Administration documents can provide unpublished evidence relevant to systematic reviews. J Clin Epidemiol. 2013;66(10):1071–81.CrossRefPubMed

36.

Turner EH. How to access and process FDA drug approval packages for use in research. BMJ. 2013;347:f5992.CrossRefPubMed

37.

O’Connor AB. The need for improved access to FDA reviews. JAMA. 2009;302(2):191–3.CrossRefPubMed

38.

DiNicolantonio JJ, Serebruany VL. Challenging the FDA black box warning for high aspirin dose with ticagrelor in patients with diabetes. Diabetes. 2013;62(3):669–71.CrossRefPubMedCentralPubMed

39.

Anthony M, Romero K, Malone DC, Hines LE, Higgins L, Woosley RL. Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium. Clin Pharmacol Ther. 2009;86(4):425–9.CrossRefPubMed

40.

Chao SD, Maibach HI. Lack of drug interaction conformity in commonly used drug compendia for selected at-risk dermatologic drugs. Am J Clin Dermatol. 2005;6(2):105–11.CrossRefPubMed

41.

Hines LE, Ceron-Cabrera D, Romero K, Anthony M, Woosley RL, Armstrong EP, et al. Evaluation of warfarin drug interaction listings in US product information for warfarin and interacting drugs. Clin Ther. 2011;33(1):36–45.CrossRefPubMed

42.

Food and Drug Administration. Guidance for industry: drug interaction studies—study design, data analysis, and implications for dosing and labeling recommendations: draft guidance. 2012. US Department of Health and Human Services. [cited 12/1/2014]; Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf.

43.

Food and Drug Administration. Information for Healthcare Professionals on FDA’s New Prescribing Information for Drugs. US Department of Health and Human Services. [cited 10/29/10]; Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/LawsActsandRules/ucm084189.htm.

44.

Food and Drug Administration. Indexing structured product labeling for human prescription drug and biologic products. Docket No. FDA-2010-N-0256. Federal Register. 2010;2010(75):33312–3.

45.

Horn JR, Hansten PD. Predicting the magnitude of drug interactions: the final frontier. Pharmacy Times. 2006;72.

46.

de Leon J, Spina E, Diaz FJ. Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity, use of repeated dosing, and translation into a message understandable to practicing clinicians. J Clin Psychopharmacol. 2009;29(3):201–5.CrossRefPubMed

47.

Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(6):811–9.CrossRefPubMed

48.

Floor-Schreudering A, Geerts AF, Aronson JK, Bouvy ML, Ferner RE, De Smet PA. Checklist for standardized reporting of drug–drug interaction management guidelines. Eur J Clin Pharmacol. 2014;70(3):313–8.CrossRefPubMed

49.

Verbeurgt P, Mamiya T, Oesterheld J. How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping. Pharmacogenomics. 2014;15(5):655–65.CrossRefPubMed

50.

Tamblyn R, Eguale T, Buckeridge DL, Huang A, Hanley J, Reidel K, et al. The effectiveness of a new generation of computerized drug alerts in reducing the risk of injury from drug side effects: a cluster randomized trial. J Am Med Inform Assoc. 2012;19(4):635–43.CrossRefPubMedCentralPubMed

51.

Seidling HM, Klein U, Schaier M, Czock D, Theile D, Pruszydlo MG, et al. What, if all alerts were specific—estimating the potential impact on drug interaction alert burden. Int J Med Inform. 2014;83(4):285–91.CrossRefPubMed

52.

Miura M, Tada H, Yasui-Furukori N, Uno T, Sugawara K, Tateishi T, et al. Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes. Chirality. 2005;17(6):338–44.CrossRefPubMed

53.

Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ. What is “quality of evidence” and why is it important to clinicians? BMJ. 2008;336(7651):995–8.CrossRefPubMedCentralPubMed

54.

Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–6.CrossRefPubMedCentralPubMed

55.

Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490 (2004-06-17 21:56:41).CrossRefPubMed

56.

Grade Working Group. [cited 7/28/14]; Available from: http://www.gradeworkinggroup.org/index.htm.

57.

The University of Liverpool. HEP-Drug Interactions. [cited 12/1/14]; Available from: http://www.hep-druginteractions.org/.

58.

The University of Liverpool. HIV-Drug Interactions. [cited 12/1/14]; Available from: http://www.hiv-druginteractions.org.

59.

Horn JR, Hansten, Philip D. “Classy” drug interactions. Pharmacy Times. 2005. [cited 12/1/14]; Available at: http://www.pharmacytimes.com/publications/issue/2005/2005-06/2005-06-9585.

60.

Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther. 1994;56(6 Pt 1):601–7.CrossRefPubMed

61.

Varhe A, Olkkola KT, Neuvonen PJ. Effect of fluconazole dose on the extent of fluconazole-triazolam interaction. Br J Clin Pharmacol. 1996;42(4):465–70.CrossRefPubMedCentralPubMed

62.

Hughes BM, Small RE, Brink D, McKenzie ND. The effect of flurbiprofen on steady-state plasma lithium levels. Pharmacotherapy. 1997;17(1):113–20.PubMed

63.

Phansalkar S, Desai AA, Bell D, Yoshida E, Doole J, Czochanski M, et al. High-priority drug–drug interactions for use in electronic health records. J Am Med Inform Assoc. 2012;19(5):735–43.CrossRefPubMedCentralPubMed

64.

Abarca J, Malone DC, Armstrong EP, Grizzle AJ, Hansten PD, Van Bergen RC, et al. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc (2003). 2004;44(2):136–41.CrossRef

65.

Murphy MK, Black NA, Lamping DL, McKee CM, Sanderson CF, Askham J, et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess. 1998;2(3):i–iv (1–88).PubMed

Titel: Consensus Recommendations for Systematic Evaluation of Drug–Drug Interaction Evidence for Clinical Decision Support
verfasst von: Richard T. Scheife
Lisa E. Hines
Richard D. Boyce
Sophie P. Chung
Jeremiah D. Momper
Christine D. Sommer
Darrell R. Abernethy
John R. Horn
Stephen J. Sklar
Samantha K. Wong
Gretchen Jones
Mary L. Brown
Amy J. Grizzle
Susan Comes
Tricia Lee Wilkins
Clarissa Borst
Michael A. Wittie
Daniel C. Malone
Publikationsdatum: 01.02.2015
Verlag: Springer International Publishing
Erschienen in: Drug Safety / Ausgabe 2/2015
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI: https://doi.org/10.1007/s40264-014-0262-8

Springer Medizin

Abstract

Background

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2015

Effect of An Educational Intervention to Improve Adverse Drug Reaction Reporting in Physicians: A Cluster Randomized Controlled Trial

Safety Surveillance of Traditional Chinese Medicine: Current and Future

Risk of Anaphylaxis with Repeated Courses of Rasburicase: A Research on Adverse Drug Events and Reports (RADAR) Project

Treating Severe Malaria in Pregnancy: A Review of the Evidence

Cancer Chemotherapy and Cardiac Arrhythmias: A Review

Specialist Cohort Event Monitoring Studies: A New Study Method for Risk Management in Pharmacovigilance